[The antipsychotic drug aripiprazole (ABILIFY)].
Hirose
Tsuyoshi
T
t_hirose@research.otsuka.co.jp
Mamiya
Noriyuki
N
Yamada
Sakiko
S
Taguchi
Masaru
M
Kameya
Teruchika
T
Kikuchi
Tetsuro
T
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D002986:Clinical Trials as Topic; D006801:Humans; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D000068180:Aripiprazole